Dr. Singh’s XMRV Patents: NOW BREAST CANCER?!!!

Yes you read the title right!!  Dr. Singh, who is the XMRV expert,  filed patents May 17, 2010, and were published on the World Intellectual Property Organization website on November 18th, 2010. The XMRV Global Action has obtained the details of these patents and have posted them on their Facebook page.  Here are some of the more juicy pieces from their article.

Please note that all of the following is written by XMRV Global Action. To view their Facebook page and the entire article:
http://www.facebook.com/notes/xmrv-global-action/dr-singhs-xmrv-patents-ground-shaking-revelations-on-xmrv-breast-cancer-prostate/472237776796

Dr Singh’s XMRV Patents: Ground-shaking revelations on XMRV, Breast Cancer, Prostate Cancer, and ME/CFS

by XMRV Global Action on Tuesday, November 23, 2010 at 2:56am

(WO/2010/132886) COMPOSITIONS AND METHODS RELATING TO XMRV-RELATED DISEASES AND CONDITIONS

From:  http://www.wipo.int/pctdb/en/wo.jsp?WO=2010132886&IA=US2010035144&DISPLAY=DESC

Note:  the titles in caps are ours – the rest are direct quotes from the patent application

DIAGNOSIS OF XMRV INFECTION AND XMRV-RELATED DISEASES

Disclosed herein are methods and compositions relating to the diagnosis of XMRV infection and XMRV-related diseases, including but not limited to malignancies such as prostate cancer, lymphomas, leukemias, myelodysplastic diseases, thymomas and also non-cancerous conditions such as chronic fatigue syndrome, and other neuroimmune disorders. The methods involve detection of XMRV RNA or DNA, or XMRV proteins, or antibodies to XMRV, and the use of these methods for diagnosis, for monitoring the progression of disease, and in monitoring treatment efficacy of various XMRV-associated diseases. Also disclosed herein are methods and compositions relating to the assessment of the cancer grade and long-term prognosis of a subject with cancer through the detection of anti-XMRV antibodies.

XMRV HAS STRONG LINK TO PROSTATE AND BREAST CANCER; DR SINGH IS RESEARCHING ASSOCIATIONS WITH ME/CFS

[0003] The present inventors discovered that Xenotropic murine leukemia-related retrovirus (XMRV) has a strong link with human cancer, including prostate cancer and breast cancer. XMRV may also be associated with cervical cancer, hematologic malignancies, including lymphomas and leukemias, and non-cancerous conditions such as chronic fatigue syndrome and other neuroimmune diseases.

DIAGNOSING WHETHER A PATIENT HAS – OR IS AT RISK TO DEVELOP – AN XMRV-RELATED DISEASE

[0005] In one aspect, the disclosure provides a method of diagnosing a subject having, or at risk of contracting, a XMRV related disease comprising: screening a sample from the subject for the presence of XMRV; and determining the presence or absence of XMRV in the sample, wherein the presence of XMRV in the sample indicates that the subject has, or is at risk of contracting, an XMRV related disease selected from the group consisting of: prostate cancer, breast cancer, hematological malignancies, other malignancies in tissues that respond to steroid hormones, such as cervix, endometrium, adrenal glands etc. In one embodiment, the XMRV related disease is breast cancer. In another embodiment the XMRV related disease is prostate cancer. In another embodiment, the XMRV related disease is hematological malignancies. In another embodiment, the XMRV related disease is chronic fatigue syndrome and other neuroimmune illnesses.

XMRV, CANCER AGGRESSIVENESS, AND PROGNOSIS IN PROSTATE CANCER

…..the presence of XMRV is an indication of an aggressive form of the cancer (prostate ca) and a poor prognosis for the patient.

XMRV FOUND IN TISSUE AND FLUIDS

[0012] In some embodiments of any of the present methods, the sample is selected from the group consisting of: saliva, semen, peritoneal fluid, synovial fluid, prostatic secretions, cervical secretions, blood, serum, plasma, tissue, and cells. In one embodiment, the sample is tissue selected from the group consisting of prostate tissue, breast tissue lymph nodes, or bone marrow. In one embodiment, the sample is prostate tissue. In one embodiment, the XMRV virus is detected in the epithelial cells or stromal cells of the prostate tissue sample, for example, in malignant epithelial cells and/or benign stromal cells. In one embodiment, the XMRV virus is detected in malignant epithelial cells of the breast tissue sample. In one embodiment, the XMRV virus is detected in immune cells in lymph nodes, bone marrow and peripheral blood from hematological malignancies. In some embodiments, the sample includes Leydig cells from testes. In other embodiments, the sample is blood, plasma or serum from a subject meeting the diagnostic criteria of chronic fatigue syndrome.

XMRV PRESENCE CORRELATED WITH CANCER GRADE

Presence of detectable XMRV DNA and/or protein is correlated with the prostate cancer grade. Figure 5B shows among 233 unselected cases of prostate cancer, XMRV was detected in approximately 19% of patients with a Gleason score of 6, 27% of those with a Gleason score of 7, 29% of those with a Gleason score of 8, and 44% of those with a Gleason score of 9.

MORE ON XMRV AND BREAST CANCER

[0025] Figure 11 shows a section from a case of breast cancer processed by IHC using anti-XMRV antisera. Malignant cells are stained brown, indicating that XMRV proteins are expressed in those cells. Adjacent benign epithelial cells show no staining.

METICULOUSLY ADDRESSING THE CONTAMINATION ISSUE

[0094] It was important to ensure that the assay specifically amplified XMRV sequences and not other murine or human endogenous retroviral sequences. In research laboratories, human tissue blocks are often sectioned on the same microtomes used for murine tissues, and contamination with murine samples can result in non-specific amplification of exogenous or endogenous murine retroviruses that are present in multiple copies in the mouse genome and have high sequence similarity to XMRV (Figure 2A). Systematic scanning of the XMRV genome identified a region of the putative gag gene that was 100% conserved between all published XMRV clones (total of 3), and yet shared at most 80% similarity with the most closely related 11 murine retroviral sequences (Figure 2A). Primers and probes in this region allowed efficient detection of XMRV without interference from related murine retroviral sequences….

ENSURING SPECIFICITY TO RULE OUT DETECTION OF MURINE ENDOGENOUS RETROVIRUSES

To test for amplification of murine ERVs, genomic DNA of a C57BL/6 mouse was used as template. To rule out amplification of human ERVs or other human sequences related to XMRV, commercially available human placental DNA was used as template. Also mouse DNA was mixed with human placental DNA at different ratios. No amplification product was observed in any of the reactions, showing that the qPCR assay was highly specific for XMRV.

ODDS OF FINDING XMRV IN PROSTATE CANCER

… The odds for XMRV being detected in prostate tissues from men with prostate cancer was more than 5 times higher than those for XMRV being present in tissue samples from men without prostate cancer (OR = 5.7, p « 0.001). A correlation of XMRV with cancer is also supported by the fact that XMRV protein was identified predominantly in malignant epithelial cells.

25% OF BREAST CANCERS CONTAINED XMRV!

…. 178 cases of breast cancer were examined for the presence of XMRV using the described methods.

Approximately 25% of breast cancers contained either XMRV proviral DNA sequences or XMRV proteins. The XMRV proteins were seen exclusively in the malignant breast epithelium (Figure 11).

XMRV PLAYS A ROLE IN PROSTATE CANCER DEVELOPMENT OR PROGRESSION

…. XMRV was identified in up to 23% of prostate cancer tissues and localized XMRV protein almost exclusively to neoplastic epithelial cells. This latter finding indicates that XMRV plays a role in cancer development or progression through one of the several direct mechanisms that have been well characterized for known oncogenic retroviruses.

ABOUT POSSIBLE SEXUAL TRANSMISSION

…. [0126] Detection of XMRV sequences in ce rvical fluid It is still unknown by which route XMRV infects people. Related retroviruses spread through transfer of blood or body fluids from an infected person to a healthy person. The ability to detect XMRV in cervical fluids as described here has allows for determining a possible route of spread of virus, including spread from mother to infant during childbirth, and has important implications for public health. Furthermore, detection of XMRV in cervical fluids offers a non-invasive method to detect XMRV.

MORE CONTROL RESULTS IN THE 5-10% RANGE:  THE PLOT THICKENS – AND THE ICE THINS, ESPECIALLY FOR THE CONTAMINATION ADVOCATES

XMRV sequences by PCR (were found)  in approximately 5-10% of samples from women on whom a test to detect other viruses (such as human papilloma virus, or herpes simplex virus) had been ordered.

XMRV IN SEMEN

…. The ability to detect XMRV in semen is also important to determine possible routes of XMRV transmission….

XMRV DNA or RNA was found in approximately 7% of all samples tested, indicating that XMRV is present in semen obtained from otherwise healthy men who are not known to have prostate cancer or chronic fatigue syndrome, or other XMRV-associated conditions. This finding has important implications for viral spread, and tests for detection of XMRV in semen have an application in testing donor semen samples used in fertility clinics.

In conclusion… This. Is. Big.

With thanks to mecfsforums and JMK for the initial scoop here:

http://www.mecfsforums.com/index.php/topic,3589.0.html

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

And there was no Breast Cancer study ever published!!!!

I would greatly encourage you to go and read the full article.  The implications of all this is mind-boggling!!

Have a Great Day!!

Donna



Advertisements

About Donna

I am a Certified Reiki Practitioner, freelance writer, poet and mentor of Life.
This entry was posted in RESEARCH/STUDIES and tagged , , , , . Bookmark the permalink.

2 Responses to Dr. Singh’s XMRV Patents: NOW BREAST CANCER?!!!

  1. Pingback: World Spinner

Comments are closed.